An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis
Latest Information Update: 25 Feb 2025
At a glance
- Drugs Deucravacitinib (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Acronyms POETYK Long-Term Extension; POETYK PSO-LTE
- Sponsors Bristol-Myers Squibb
- 16 Feb 2025 According to a Bristol-Myers Squibb Media Release, new five-year result data were presented at the Winter Clinical Dermatology Conference Hawaii (WCH) in Big Island, Waikoloa Village, HI taking place February 14-19, 2025.
- 16 Feb 2025 New five-year result presented in the Bristol-Myers Squibb Media Release.
- 15 Jun 2024 Results of Maintenance of Response over 3 Years, presented at the 25th Annual Congress of the European League Against Rheumatism